智通财经APP讯,亚盛医药-B(06855)发布公告,公司共有五项临床前研究进展入选2025年美国癌症研究协会(AACR)年会。此次会议将于2025年4月25日至2025年4月30日在美国芝加哥举行。
本次将要展示的数据涉及公司五个品种,包括:原创1类新药奥雷巴替尼(商品名:耐立克®;研发代号:HQP1351)、Bcl-2抑制剂APG-2575、FAK/ALK/ROS1三联酪氨酸激酶抑制剂APG-2449、胚胎外胚层发育蛋白(EED)抑制剂APG-5918以及IAP拮抗剂AS03157。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.